FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2760246232> ?p ?o ?g. }

• W2760246232 endingPage "3039" @default.
• W2760246232 startingPage "3039" @default.
• W2760246232 abstract "3039 Background: PICN is a novel solvent and protein-free 100-110 nm particle formulation of paclitaxel stabilized with polymer and lipid using Nanotecton Technology. Paclitaxel has shown superior safety and efficacy profile when administered on a weekly schedule. We studied safety, tolerability, and pharmacokinetics (PK) of PICN using a weekly schedule in patients with advanced solid malignancies. Methods: Patients aged18-65 years with advanced solid malignancies, ECOG performance status ≤ 2, estimated survival ≥ 12 weeks, and adequate organ function were enrolled. A standard phase I, 3+3 dose escalation design to determine the maximum tolerated dose (MTD) of PICN administered on a weekly schedule (three consecutive weeks, one week recovery) was employed. PICN dose was escalated at pre-determined fixed dose levels of 80, 100, 125, 150, 175, and 200 mg/m 2 . PICN was administered as a 30 min infusion without any premedication for hypersensitivity. Results: Twenty-one patients treated with PICN had a mean age of 52.1 yrs (range 35-67); 20 were female and entered with metastatic breast cancer (MBC; n=15), cervical cancer (n=3), skin cancer (n=2). One male had oral cancer. Doses studied were 80 (n=3), 100 (n=3), 125 (n=3), 150 (n=3), 175 (n=6), and 200 (n=3) mg/m 2 . Despite the lack of dexamethasone premedication, no patient receiving PICN reported hypersensitivity reaction. Two DLTs (neutropenia and febrile neutropenia; both grade 3) were reported at PICN 200 mg/m 2 . PICN PK (AUC 0-24, AUC 0-∞, and C max ) increased in a dose proportionate manner from 80 to 200 mg/m 2 . Grade 3 or worse related AEs were: neutropenia, leucopenia, peripheral neuropathy, febrile neutropenia, anemia, thrombocytopenia, fatigue, syncope, hypotension and maculopapular rash. Partial responses were observed in MBC (100, 125, 150, 175, and 200 mg/m 2 ) and cervical cancer (80 mg/m 2 ). Conclusions: PICN on thrice monthly schedule was tolerable in the dose range evaluated. Two DTLs were reported: neutropenia and febrile neutropenia (both grade 3). Anti-tumor activity was observed in MBC and cervical cancer. Final trial data for PICN PK, safety, and efficacy will be presented at the conference. Clinical trial information: CTRI/2011/11/002124." @default.
• W2760246232 created "2017-10-06" @default.
• W2760246232 creator A5003701266 @default.
• W2760246232 creator A5013507171 @default.
• W2760246232 creator A5016745365 @default.
• W2760246232 creator A5017657024 @default.
• W2760246232 creator A5027534876 @default.
• W2760246232 creator A5057427943 @default.
• W2760246232 creator A5080941476 @default.
• W2760246232 date "2013-05-20" @default.
• W2760246232 modified "2023-09-25" @default.
• W2760246232 title "Phase I study of weekly treatment with paclitaxel injection concentrate for nanodispersion (PICN), a novel solvent and protein-free formulation of paclitaxel." @default.
• W2760246232 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.3039" @default.
• W2760246232 hasPublicationYear "2013" @default.
• W2760246232 type Work @default.
• W2760246232 sameAs 2760246232 @default.
• W2760246232 citedByCount "1" @default.
• W2760246232 countsByYear W27602462322023 @default.
• W2760246232 crossrefType "journal-article" @default.
• W2760246232 hasAuthorship W2760246232A5003701266 @default.
• W2760246232 hasAuthorship W2760246232A5013507171 @default.
• W2760246232 hasAuthorship W2760246232A5016745365 @default.
• W2760246232 hasAuthorship W2760246232A5017657024 @default.
• W2760246232 hasAuthorship W2760246232A5027534876 @default.
• W2760246232 hasAuthorship W2760246232A5057427943 @default.
• W2760246232 hasAuthorship W2760246232A5080941476 @default.
• W2760246232 hasConcept C126322002 @default.
• W2760246232 hasConcept C141071460 @default.
• W2760246232 hasConcept C197934379 @default.
• W2760246232 hasConcept C2776694085 @default.
• W2760246232 hasConcept C2777063308 @default.
• W2760246232 hasConcept C2778300832 @default.
• W2760246232 hasConcept C2778375690 @default.
• W2760246232 hasConcept C71924100 @default.
• W2760246232 hasConcept C90924648 @default.
• W2760246232 hasConceptScore W2760246232C126322002 @default.
• W2760246232 hasConceptScore W2760246232C141071460 @default.
• W2760246232 hasConceptScore W2760246232C197934379 @default.
• W2760246232 hasConceptScore W2760246232C2776694085 @default.
• W2760246232 hasConceptScore W2760246232C2777063308 @default.
• W2760246232 hasConceptScore W2760246232C2778300832 @default.
• W2760246232 hasConceptScore W2760246232C2778375690 @default.
• W2760246232 hasConceptScore W2760246232C71924100 @default.
• W2760246232 hasConceptScore W2760246232C90924648 @default.
• W2760246232 hasIssue "15_suppl" @default.
• W2760246232 hasLocation W27602462321 @default.
• W2760246232 hasOpenAccess W2760246232 @default.
• W2760246232 hasPrimaryLocation W27602462321 @default.
• W2760246232 hasRelatedWork W1968996867 @default.
• W2760246232 hasRelatedWork W2022476615 @default.
• W2760246232 hasRelatedWork W2040098975 @default.
• W2760246232 hasRelatedWork W2074843056 @default.
• W2760246232 hasRelatedWork W2172224933 @default.
• W2760246232 hasRelatedWork W21740694 @default.
• W2760246232 hasRelatedWork W2389274629 @default.
• W2760246232 hasRelatedWork W2409130183 @default.
• W2760246232 hasRelatedWork W2409218464 @default.
• W2760246232 hasRelatedWork W4233629407 @default.
• W2760246232 hasVolume "31" @default.
• W2760246232 isParatext "false" @default.
• W2760246232 isRetracted "false" @default.
• W2760246232 magId "2760246232" @default.
• W2760246232 workType "article" @default.